Ehime, Japan, March 4th, 2025 – Optieum Biotechnologies Inc. (“Optieum”), a preclinical stage company dedicated to the discovery and development of innovative CAR-T cell therapies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted and registered patent number US 12,241,061 B for its core platform technology, the Eumbody System. This achievement strengthens Optieum’s intellectual property foundation as the company progresses from discovery-stage research towards clinical development.
“The granting of this patent in the U.S. is a pivotal milestone for Optieum and underscores the uniqueness and strength of the Eumbody System,” said Shun Nishioka, CEO of Optieum Biotechnologies. “This technology has the potential to redefine how CAR-T therapies are developed, paving the way for more effective treatments for patients in need, the first of which we are now moving forward towards an Investigational New Drug (IND) filing in the U.S. for the treatment of glioblastoma (GBM).”
Based on international patent application (WO2020/162452) and following on from previously granted patents in Japan (Patent No. 6821230, etc.) and Australia (AU 2020218446 B2), the United States is now the third jurisdiction to grant protection for this innovative platform.
Optieum remains committed to advancing the field of CAR-T cell therapy through continuous innovation and rigorous scientific research. The company’s Eumbody System serves as the foundation for its growing pipeline of next-generation CAR-T candidates, aimed at addressing some of the most challenging unmet medical needs.
For more information about Optieum and the Eumbody System, please visit www.optieumbio.com.
The Eumbody System represents a breakthrough in CAR-T cell therapy development. This proprietary platform leverages rapid and expansive functional screening to identify and optimize CAR constructs in unprecedented fashion. By dynamically harmonizing single-chain variable fragment (scFv) sequences through empirical evaluation, the Eumbody System significantly enhances the functional capabilities of T cells, setting a new standard in CAR-T innovation.
Optieum Biotechnologies Inc. is a cutting-edge biotechnology company dedicated to engineering hope for patients through the development of next-generation CAR-T cell therapies. At the heart of Optieum’s innovation is its proprietary Eumbody System, a revolutionary platform that optimizes CAR constructs to unlock the full therapeutic potential of T cells by dynamically harmonizing CAR binding domains. This transformative platform has the potential to redefine CAR-T cell therapy, enabling the development of groundbreaking treatments for challenging diseases. For more information, visit www.optieumbio.com and follow us on LinkedIn.
Optieum Biotechnologies
Email: info@optieumbio.com
